- Home
- RCKT vs AVIR Comparison
RCKT vs AVIR Comparison
Compare RCKT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | AVIR |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | 202 | 55 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.6M | 399.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RCKT | AVIR |
|---|---|---|
| Price | $3.91 | $4.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $29.73 | $10.00 |
| AVG Volume (30 Days) | ★ 3.2M | 356.0K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $64.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $2.78 |
| 52 Week High | $5.45 | $6.45 |
Technical Indicators
Market Signals| Indicator | RCKT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 64.16 | 60.55 |
| Support Level | $3.01 | $4.14 |
| Resistance Level | $4.04 | $5.04 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 69.32 | 83.67 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.